Supreme Court Signals Doubts Over Trump’s Bid to Fire Fed Governor Lisa Cook 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
Trump Administration Appeals Judge’s Order Limiting ICE Tactics in Minneapolis 
Trump Family Files $10 Billion Lawsuit Over IRS Tax Disclosure 
Google Halts UK YouTube TV Measurement Service After Legal Action 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Oil Prices Hit Four-Month High as Geopolitical Risks and Supply Disruptions Intensify 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
China Home Prices Rise in January as Government Signals Stronger Support for Property Market 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
